Table 1.
Characteristics of studies included in the meta-analysis
| AUGUSTUS | ENTRUST AF-PCI | PIONEER AF-PCI | RE-DUAL PCI | WOEST | |
|---|---|---|---|---|---|
| First author/ Publication year | Renato D. Lopes /2019 | Pascal Vranckx /2019 | C. Michael Gibson/2016 | Christopher P. Cannon/2017 | Willem J M Dewilde/2013 |
| Antithrombotic drug strategy (composition of antithrombotic drug strategy) | Apixaban + P2Y12 inhibitor and Aspirin/ Apixaban + P2Y12 inhibitor and Placebo/ VKA + P2Y12 inhibitor and Aspirin/ VKA + P2Y12 inhibitor and Placebo Or : Apixaban/VKA /Aspirin / Aspirin-Matched Placebo | Edoxaban + a P2Y12 inhibitor for 12 months/ a VKA in combination with a P2Y12 inhibitor and aspirin for 1–12 months | Low-dose rivaroxaban + a P2Y12 inhibitor for 12 months/ very-low-dose rivaroxaban + DAPT for 1, 6, or 12 months/ a dose-adjusted VKA (once daily) + DAPT for 1, 6, or 12 months | Dual therapy with dabigatran (110 mg twice daily) + a P2Y12 inhibitor (clopidogrel or ticagrelor)/ Triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1 to 3 months)/ Dual therapy with dabigatran (150 mg twice daily) + a P2Y12 inhibitor (clopidogrel or ticagrelor)/ Corresponding triple therapy with warfarin with dual therapy with dabigatran (150 mg twice daily) group | OAC + clopidogrel alone (double therapy)/ OAC + clopidogrel + aspirin (triple therapy) |
| The number of people with different drug strategies (n = ) | 1153/1153/1154/1154 Apixaban/ VKA/ Aspirin/ Aspirin-Matched Placebo (2306/2308/2307/2307) | 751/755 | 709/709/706 | 981/981/763/764 | 279/284 |
| Follow-up time (month) | 6 (additional visit at month 7) | 12 | 12 | Median: 14 | 12 |
| Creatinine clearance (ml/min) [mean (SD)] (experimental group/ control group) | NR | 71.8(53.7–91.1)/71.7(54.0–90.9) | 78.3 ± 31.3/77.5 ± 31.8/80.7 ± 30.0 | 76.3 ± 28.9/75.4 ± 29.1/83.7 ± 31.0/81.3 ± 29.6 | NR |
| Type of index event [n(%)] | ACS and PCI:873(38.0)/841(36.6)/844(36.8)/870(37.8) Medically managed ACS: 547(23.8)/550(23.9)547(23.9)/550(23.9) Elective PCI: 877(38.2)/907(39.5) 902(39.3)/882(38.3) | ACS: 388(52)/389(52) Stable coronary artery disease: 363(48)/366(48) | Non-ST elevation myocardial infarction: 130(18.5)/129(18.3)/123(17.8) ST elevation myocardial infarction: 86(12.3)/97(13.8)/74(10.7) Unstable angina : 145(20.7)/148(21.1)/164(23.7) | Stable angina or positive stress test: 433(44.1)/429(43.7)/320(41.9)/339(44.4) ACS: 509(51.9)/475(48.4)/391(51.2)/369(48.3) Staged procedure: 156(15.9)/168(17.1)/138(18.1)/134(17.5) Other: 43(4.4)/62(6.3)/65(8.5)/50(6.5) | ACS: 69(25)/86(30) |
| Diabetes mellitus [n(%)] (experimental group/ control group) | 842(36.5)/836(36.2)/842(36.5)/836(36.2) | 259(34)/258(34) | 204(28.8)/199(28.1)/221(31.3) | 362(36.9)/371(37.9)/260 (34.1)/303(39.7) | 68(24)/72(25) |
| Hypertension [n(%)] (experimental group/ control group) | 2042(88.6)/2031(88.0)/2031(88.0)/2042(88.5) | 674(90)/687(91) | 520(73.3)/519(73.2)/532(75.4) | NR | 193(69)/193(68) |
| Prior myocardial infarction [n(%)] (experimental group/ control group) | NR | 188(25)/177(23) | 140(19.8)/180(25.4)/157(22.2) | 237(24.2)/268(27.3)/194(25.4)/211(27.6) | 96(34)/100(35) |
| Prior stroke [n(%)] (experimental group/ control group) | NR | 97(13)/92(12) | NR | 74(7.5)/100(10.2)/52(6.8)/77(10.1) | 49(18)/50(18) |
NR: not reported. OAC: oral anticoagulant. VKA: vitamin K antagonist. DAPT: dual antiplatelet therapy. ACS: acute coronary syndrome